Publications

Nayar U, Lu P, Goldstein RL, Vider J, Ballon G, Rodina A, Taldone T, Erdjument-Bromage H, Chomet M, Blasberg R et al..  2013.  Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies.. Blood. 122(16):2837-47.

Barish GD, Yu RT, Karunasiri MS, Becerra D, Kim J, Tseng TW, Tai L-J, Leblanc M, Diehl C, Cerchietti L et al..  2012.  The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis.. Cell Metab. 15(4):554-62.

Fontan L, Yang C, Kabaleeswaran V, Volpon L, Osborne MJ, Beltran E, Garcia M, Cerchietti L, Shaknovich R, Yang SNing et al..  2012.  MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo.. Cancer Cell. 22(6):812-24.

Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, Swaminathan S, Klemm L, Kweon S-mi, Nahar R, Braig M et al..  2011.  BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition.. Nature. 473(7347):384-8.

Shaknovich R, Cerchietti L, Tsikitas L, Kormaksson M, De S, Figueroa ME, Ballon G, Yang SNing, Weinhold N, Reimers M et al..  2011.  DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation.. Blood. 118(13):3559-69.

Cerchietti L, Damm-Welk C, Vater I, Klapper W, Harder L, Pott C, Yang SNing, Reiter A, Siebert R, Melnick A et al..  2011.  Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas.. PLoS One. 6(4):e18436.

Ci W, Polo JM, Cerchietti L, Shaknovich R, Wang L, Yang SNing, Ye K, Farinha P, Horsman DE, Gascoyne RD et al..  2009.  The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL.. Blood. 113(22):5536-48.

Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y et al..  2009.  Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.. Proc Natl Acad Sci U S A. 106(20):8368-73.

Caldas-Lopes E, Cerchietti L, Ahn JH, Clement CC, Robles AI, Rodina A, Moulick K, Taldone T, Gozman A, Guo Y et al..  2009.  Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models.. Proc Natl Acad Sci U S A. 106(20):8368-73.

Cerchietti LC, Lopes EC, Yang SNing, Hatzi K, Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J, Varticovski L et al..  2009.  A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.. Nat Med. 15(12):1369-76.

Bonomi M, Blanco-Savorio A, Cerchietti L, Navigante A, Castro M, Roth B, Wisnivesky JP.  2008.  Continuous hyperfractionated accelerated radiation therapy week-end less in combination with neoadjuvant chemotherapy for the treatment of stage III non-small-cell lung cancer.. Lung Cancer. 60(1):75-82.